Recent Surge: Iovance Biotherapeutics (IOVA) has sparked lively discussion on X recently, driven by a notable stock price jump. Many users are pointing to promising interim results from a Phase 2 trial of their TIL therapy, lifileucel, as a key catalyst. Posts highlight optimism around the therapy’s potential in treating advanced non-small cell lung cancer.
Sales Momentum: Another focal point on X is the strong sales growth of Iovance’s Amtagvi, with quarterly revenue reportedly surpassing $60 million. Discussions note a year-over-year increase of over 90%, fueling excitement about the company’s financial trajectory. Some users also mention restructuring efforts aimed at cost savings, adding to the positive buzz.
Cautious Voices: Despite the enthusiasm, there are cautious takes on X about challenges like therapy scalability and potential revenue shortfalls. A few posts warn of risks tied to regulatory hurdles or physician hesitancy regarding treatment efficacy. The conversation remains dynamic, with a mix of bullish and skeptical perspectives.
Note: This discussion summary was generated from an AI condensation of post data.
Iovance Biotherapeutics Insider Trading Activity
Iovance Biotherapeutics insiders have traded $IOVA stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IOVA stock by insiders over the last 6 months:
- DANIEL GORDON KIRBY (Chief Commercial Officer) purchased 30,000 shares for an estimated $55,200
- RAJ K. PURI (Chief Regulatory Officer) purchased 5,600 shares for an estimated $9,743
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Iovance Biotherapeutics Hedge Fund Activity
We have seen 134 institutional investors add shares of Iovance Biotherapeutics stock to their portfolio, and 159 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC removed 12,711,788 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,864,275
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 9,216,040 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,851,588
- MILLENNIUM MANAGEMENT LLC added 9,171,900 shares (+5793.2%) to their portfolio in Q2 2025, for an estimated $15,775,668
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,120,135 shares (-88.6%) from their portfolio in Q2 2025, for an estimated $8,806,632
- MACQUARIE GROUP LTD removed 4,791,235 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,240,924
- MHR FUND MANAGEMENT LLC added 4,550,000 shares (+18.6%) to their portfolio in Q2 2025, for an estimated $7,826,000
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 4,523,293 shares (-58.1%) from their portfolio in Q2 2025, for an estimated $7,780,063
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Iovance Biotherapeutics Analyst Ratings
Wall Street analysts have issued reports on $IOVA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/29/2025
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- Chardan Capital issued a "Buy" rating on 07/23/2025
- Goldman Sachs issued a "Buy" rating on 05/12/2025
- Mizuho issued a "Outperform" rating on 05/12/2025
- Barclays issued a "Overweight" rating on 05/12/2025
To track analyst ratings and price targets for Iovance Biotherapeutics, check out Quiver Quantitative's $IOVA forecast page.
Iovance Biotherapeutics Price Targets
Multiple analysts have issued price targets for $IOVA recently. We have seen 7 analysts offer price targets for $IOVA in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $9.0 on 10/29/2025
- Yanan Zhu from Wells Fargo set a target price of $14.0 on 08/08/2025
- Geulah Livshits from Chardan Capital set a target price of $20.0 on 08/08/2025
- David Dai from UBS set a target price of $2.0 on 05/16/2025
- Andrea Tan from Goldman Sachs set a target price of $8.0 on 05/12/2025
- Mara Goldstein from Mizuho set a target price of $10.0 on 05/12/2025
- Peter Lawson from Barclays set a target price of $4.0 on 05/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
